查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1530330

全球無菌注射 CDMO 市場：市場規模、佔有率和趨勢分析 - 按分子、按產品、按服務、按治療領域、按給藥途徑、按最終用途、按地區、細分市場預測，2024-2030 年

Sterile Injectables CDMO Market Size, Share & Trends Analysis Report By Molecule (Small Molecule, Large Molecule), By Product, By Service, By Therapeutic Area, By Route of Administration, By End Use, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

預計2023年全球無菌注射CDMO市場規模將達39.4億美元，2024年至2030年複合年成長率為9.92%。

市場成長主要是由於注射藥物的管道和核准的增加。製藥公司正在積極致力於開發注射藥物，這種藥物具有許多優勢，包括起效更快、劑量更精確以及提高患者依從性。例如，根據美國食品藥物管理局（FDA）2024年1月發布的報告，藥物評估與研究中心（CDER）在2023年核准了55種新藥。這些藥物還包括注射劑，顯示產品線很強大。該管道預計將推動商業和研究目的契約製造服務的需求增加，從而促進整體市場的成長。

對細胞和基因治療的需求不斷成長正在推動市場成長。隨著治療產品線的擴大，對受託製造廠商(CMO) 提供的專業製造能力的需求也在增加。例如，根據 ClinicalTrials.gov 的數據，截至 2024 年 3 月，北美有超過 581 項臨床試驗專注於細胞療法和治療各種疾病的相關方法，預計在整個預測期內契約製造將會增加。

此外，市場參與企業的策略性舉措，例如擴大無菌生產設施和協作研究/夥伴關係，預計將在整個預測期內促進市場成長。例如，2023年11月，NorthEdge將投資Torbay Pharmaceuticals，以支持未來的國際擴張。 2023 年 3 月，PCI Pharma Services 宣布對其伊利諾州羅克福德工廠進行 5,000 萬美元的擴建計劃。該計劃將包括建造一座 20 萬平方英尺的新大樓，以提高注射藥物和器械組合產品的生產能力。

對無菌注射劑的高需求正在推動契約製造製造商和生物製藥公司之間委託協議的成長，從而推動無菌注射劑 CDMO 行業的成長。對快速藥效、快速吸收和較低藥物濃度的需求不斷成長，是推動無菌注射 CDMO 行業採用的一些關鍵方面。此外，積極參與無菌注射劑開發和製造的製藥公司也擴大支持單株抗體療法、大分子注射劑和感染疾病治療藥物。有幾個因素正在加速全球市場上無菌注射 CDMO 的成長，包括研發週期縮短時間、非專利藥注射成本降低以及罕見疾病治療的進步。

此外，先進的製造技術對於確保抗癌藥物的穩定性和功效至關重要。專門從事無菌注射劑的契約製造製造商，特別是那些在複雜配方和生技藥品方面擁有豐富經驗的製造商，有能力滿足癌症藥物的獨特要求。無菌注射劑對於在癌症治療中提供複雜的生技藥品和創新治療方法至關重要，並且正在推動無菌注射契約製造製造業的成長。預計外包的成長將在預測期內推動該產業的擴張。製藥公司，特別是專注於腫瘤學的製藥公司，擴大轉向外包製造業務，以簡化流程、降低成本並利用製造外包提供的專業知識。這一轉變極大地促進了癌症領域無菌注射藥物的合約開發和受託製造市場。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第 3 章 無菌注射 CDMO 市場變數、趨勢與範圍

  • 市場體系展望
  • 市場動態
  • 技術進步
  • 定價模式分析
  • 臨床試驗定量分析，2023
  • 無菌注射 CDMO 市場：分析工具
  • COVID-19 影響分析

第 4 章 無菌注射 CDMO 市場：分子估計與趨勢分析

  • 細分儀表板
  • 全球無菌注射CDMO市場波動分析
  • 2018-2030年全球無菌注射CDMO市場規模及趨勢分析（依分子）
  • 低分子
  • 聚合物

第5章無菌注射 CDMO 市場：產品估算與趨勢分析

  • 細分儀表板
  • 全球無菌注射CDMO市場波動分析
  • 2018-2030年全球無菌注射CDMO市場規模及趨勢分析（依產品）
  • 無菌注射液
  • 預填充式注射器
  • 管瓶/安瓿

第6章無菌注射 CDMO 市場：服務評估與趨勢分析

  • 細分儀表板
  • 全球無菌注射CDMO市場波動分析
  • 2018-2030年全球無菌注射CDMO市場規模及趨勢分析（依服務）
  • 合約開發
  • 契約製造
  • 包裝
  • 品管/保證
  • 冷凍乾燥服務

第7章無菌注射CDMO市場：治療領域的估算與趨勢分析

  • 細分儀表板
  • 全球無菌注射CDMO市場波動分析
  • 2018-2030年全球無菌注射CDMO市場規模及趨勢分析、治療領域
  • 腫瘤學
  • 循環系統疾病
  • 法律代表
  • 中樞神經系統疾病
  • 感染疾病
  • 肌肉骨骼疾病
  • 荷爾蒙疾病
  • 其他

第8章無菌注射CDMO市場：給藥途徑預估及趨勢分析

  • 細分儀表板
  • 全球無菌注射CDMO市場波動分析
  • 2018-2030年全球無菌注射CDMO市場規模及趨勢分析、給藥途徑
  • 皮下注射（SC）
  • 靜脈注射 (IV)
  • 肌肉注射 (IM)
  • 其他

第 9 章 無菌注射 CDMO 市場：最終用途估計與趨勢分析

  • 細分儀表板
  • 全球無菌注射CDMO市場波動分析
  • 2018-2030年全球無菌注射CDMO市場規模與趨勢分析、最終用途
  • 製藥公司
  • 生物製藥公司
  • 其他

第10章無菌注射CDMO市場：區域估計與趨勢分析

  • 區域市場儀表板
  • 全球區域市場概述
  • 2018-2030年市場規模、預測趨勢分析：
  • 北美洲
    • 2018-2030 年北美市場估計與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 2018-2030 年歐洲市場估計與預測
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 2018-2030 年亞太市場估計與預測
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 2018-2030 年拉丁美洲市場估計與預測
    • 巴西
    • 阿根廷
  • 中東/非洲
    • 2018-2030 年中東和非洲市場估計和預測
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第11章競爭格局

  • 市場參與企業分類
    • 市場領導
    • 新興玩家
  • 服務熱圖分析
  • 公司簡介
    • Boehringer Ingelheim GmbH
    • Boehringer Ingelheim GmbH
    • Vetter Pharma
    • Recipharm AB
    • Aenova Group
    • Fresenius Kabi
    • Famar
    • NextPharma Technologies
    • Ajinomoto Bio-Pharma Services
    • PCI Pharma Services
    • IDT Biologika
    • Alcami Corporation
    • Fareva Group
    • Eurofins CDMO
    • Siegfried Holding AG
Product Code: GVR-4-68040-363-5

Sterile Injectables CDMO Market Trends

The global sterile injectables CDMO market size was estimated at USD 3.94 billion in 2023 and is projected to grow at a CAGR of 9.92% from 2024 to 2030. The market growth is primarily driven by increasing pipeline and approvals of injectable drugs. Pharmaceutical companies are proactively focusing on developing injectable medications due to their numerous benefits, such as quicker onset of action, precise dosing, and enhanced patient adherence. For instance, as per the U.S. Food and Drug Administration (FDA) report published in January 2024, the Center for Drug Evaluation and Research (CDER) approved 55 novel drugs in 2023. These medications included injectables, indicating a robust pipeline that is anticipated to drive an increase in the demand for contract manufacturing services for both commercial and research purposes, hence contributing to overall market growth.

The increasing demand for cellular and genetic therapies is driving the market's growth. With the expansion of therapy pipelines, there is a rising requirement for specialized manufacturing capabilities provided by contract manufacturing organizations (CMOs). For instance, according to ClinicalTrials.gov, as of March 2024, over 581 clinical trials were focused on cell therapies and related approaches for treating various diseases in North America is anticipated to drive an increase in contract manufacturing throughout the projected period.

Furthermore, strategic initiatives undertaken by market participants, such as expanding sterile manufacturing facilities and engaging in collaborations and partnerships, are anticipated to bolster market growth throughout the projected period. For instance, in November 2023, NorthEdge invested in Torbay Pharmaceuticals to support its upcoming phase of international expansion. In March 2023, PCI Pharma Services has announced a USD 50 million expansion project at its Rockford, Illinois facility, which will involve the construction of a new 200,000-square-foot building to increase the site's capacity for manufacturing injectable drug-device combination products.

The high demand for sterile injectables propels growth in outsourced agreements amongst contract manufacturers and biopharmaceutical companies, thereby boosting the growth of the sterile injectable CDMO industry. The growing need for faster drug action, rapid absorption, and less drug concentration are a few major aspects contributing to the adoption of sterile injectables CDMO industry. Further, pharmaceutical firms actively involved in sterile injectable development and manufacturing are gaining traction to support monoclonal antibody therapies, large-molecule injectable drugs, and infectious disease-treating drugs. Several factors, including reduced time and cost-affordable research and development cycles of generic injectables and the growing advancements in rare disease treatments, are accelerating the growth of sterile injectable CDMO's in the global market.

Moreover, advanced manufacturing techniques are crucial for ensuring the stability and efficacy of cancer therapies. Contract manufacturers specializing in sterile injectables, particularly those experienced in handling complex formulations and biologics, are well-equipped to address the specific requirements of oncology drugs. Sterile injectables are essential for delivering complex biologics and innovative treatment methods in cancer treatment, driving the growth of the sterile injectable contract manufacturing sector. The growth in outsourcing practices is expected to drive the expansion of the segment over the forecast period. Pharmaceutical companies, particularly those specializing in oncology, are increasingly turning to outsourcing manufacturing operations to streamline processes, cut costs, and capitalize on the specialized expertise offered by contract manufacturers. This shift has notably boosted the cancer sector's sterile injectable contract development and manufacturing market.

Global Sterile Injectables CDMO Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global Sterile Injectables CDMO market report based on molecule type, product, service, therapeutic area, route of administration, end use, and region:

  • Molecule Outlook (Revenue, USD Million, 2018 - 2030)
  • Small Molecule
  • Large Molecule
  • Product Outlook (Revenue, USD Million, 2018 - 2030)
  • Sterile Liquid Injectables
  • Pre-filled Syringes
  • Vials and Ampoules
  • Service Outlook (Revenue, USD Million, 2018 - 2030)
  • Contract Development
  • Contract Manufacturing
  • Packaging
  • Quality Control and Assurance
  • Lyophilization Services
  • Therapeutic Area Outlook (Revenue, USD Million, 2018 - 2030)
  • Oncology
  • Cardiovascular Diseases
  • Central Nervous System Diseases
  • Infectious Disorders
  • Musculoskeletal Diseases
  • Hormonal Diseases
  • Others
  • Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
  • Subcutaneous (SC)
  • Intravenous (IV)
  • Intramuscular (IM)
  • Others
  • End Use Outlook (Revenue, USD Million, 2018 - 2030)
  • Pharmaceutical Companies
  • Biopharmaceutical Companies
  • Others
  • Regional Outlook (Revenue, USD Million, 2018 - 2030)
  • North America

U.S.

Canada

Mexico

  • Europe

UK

Germany

France

Italy

Spain

Denmark

Sweden

Norway

  • Asia Pacific

China

Japan

India

Australia

South Korea

Thailand

  • Latin America

Brazil

Argentina

  • Middle East and Africa (MEA)

South Africa

Saudi Arabia

UAE

Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Regional Scope
    • 1.1.2. Estimates and Forecast Timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased Database
    • 1.3.2. GVR's Internal Database
    • 1.3.3. Secondary Sources
    • 1.3.4. Primary Research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data Analysis Models
  • 1.5. Market Formulation & Validation
    • 1.5.1. Region Wise Market: Base Estimates
    • 1.5.2. Global Market: CAGR Calculation
  • 1.6. Model Details
    • 1.6.1. Commodity Flow Analysis (Model 1)
    • 1.6.2. Value-Chain-Based Sizing & Forecasting (Model 2)
    • 1.6.3. QFD Model Sizing & Forecasting (Model 3)
    • 1.6.4. Bottom-Up Approach (Model 4)
  • 1.7. Market Definitions
  • 1.8. List of Secondary Sources
  • 1.9. List of Abbreviations
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Sterile Injectables CDMO Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing Pipeline and Approvals of Injectables
      • 3.2.1.2. Growing Demand for Biologics and Biosimilars Significantly Supported Market Growth
      • 3.2.1.3. Rise in Investment Across Research & Development Activities for the Development of Novel Therapeutics
      • 3.2.1.4. Increasing Demand for Cell & Gene Therapies
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Low Barriers to Market Penetration Have Resulted in Pricing Pressure
      • 3.2.2.2. Challenges Related to Quality Control
  • 3.3. Technological Advancements
  • 3.4. Pricing Model Analysis
  • 3.5. Clinical Trials Volume Analysis, 2023
    • 3.5.1. Total Number of Clinical Trials, by Region (2023)
    • 3.5.2. Total Number of Clinical Trials, by Phase (2023)
    • 3.5.3. Total Number of Clinical Trials, by Study Design (2023)
    • 3.5.4. Total Number of Clinical Trials, by Key Therapeutic Area (2023)
  • 3.6. Sterile Injectables CDMO Market: Analysis Tools
    • 3.6.1. Porter's Five Forces Analysis
    • 3.6.2. PESTEL Analysis
  • 3.7. COVID-19 Impact Analysis

Chapter 4. Sterile Injectables CDMO Market: Molecule Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Sterile Injectables CDMO Market Movement Analysis
  • 4.3. Global Sterile Injectables CDMO Market Size & Trend Analysis, by Molecule, 2018 to 2030 (USD Million)
  • 4.4. Small Molecule
    • 4.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 4.5. Large Molecule
    • 4.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

Chapter 5. Sterile Injectables CDMO Market: Product Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Sterile Injectables CDMO Market Movement Analysis
  • 5.3. Global Sterile Injectables CDMO Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
  • 5.4. Sterile Liquid Injectables
    • 5.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 5.5. Pre-filled Syringes
    • 5.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 5.6. Vials and Ampoules
    • 5.6.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

Chapter 6. Sterile Injectables CDMO Market: Service Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global Sterile Injectables CDMO Market Movement Analysis
  • 6.3. Global Sterile Injectables CDMO Market Size & Trend Analysis, by Service, 2018 to 2030 (USD Million)
  • 6.4. Contract Development
    • 6.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 6.5. Contract Manufacturing
    • 6.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 6.6. Packaging
    • 6.6.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 6.7. Quality Control and Assurance
    • 6.7.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 6.8. Lyophilization Services
    • 6.8.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

Chapter 7. Sterile Injectables CDMO Market: Therapeutic Area Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. Global Sterile Injectables CDMO Market Movement Analysis
  • 7.3. Global Sterile Injectables CDMO Market Size & Trend Analysis, Therapeutic Area, 2018 to 2030 (USD Million)
  • 7.4. Oncology
    • 7.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 7.5. Cardiovascular Diseases
    • 7.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 7.6. Legal Representation
    • 7.6.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 7.7. Central Nervous System Diseases
    • 7.7.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 7.8. Infectious Disorders
    • 7.8.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 7.9. Musculoskeletal Diseases
    • 7.9.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 7.10. Hormonal Diseases
    • 7.10.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 7.11. Others
    • 7.11.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

Chapter 8. Sterile Injectables CDMO Market: Route of Administration Estimates & Trend Analysis

  • 8.1. Segment Dashboard
  • 8.2. Global Sterile Injectables CDMO Market Movement Analysis
  • 8.3. Global Sterile Injectables CDMO Market Size & Trend Analysis, Route of Administration, 2018 to 2030 (USD Million)
  • 8.4. Subcutaneous (SC)
    • 8.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 8.5. Intravenous (IV)
    • 8.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 8.6. Intramuscular (IM)
    • 8.6.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 8.7. Others
    • 8.7.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

Chapter 9. Sterile Injectables CDMO Market: Modality by End Use Estimates & Trend Analysis

  • 9.1. Segment Dashboard
  • 9.2. Global Sterile Injectables CDMO Market Movement Analysis
  • 9.3. Global Sterile Injectables CDMO Market Size & Trend Analysis, End Use, 2018 to 2030 (USD Million)
  • 9.4. Pharmaceutical Companies
    • 9.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 9.5. Biopharmaceutical Companies
    • 9.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 9.6. Others
    • 9.6.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

Chapter 10. Sterile Injectables CDMO Market: Regional Estimates & Trend Analysis

  • 10.1. Regional Market Dashboard
  • 10.2. Global Regional Market Snapshot
  • 10.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 10.4. North America
    • 10.4.1. North America Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.4.2. U.S.
      • 10.4.2.1. Key Country Dynamics
      • 10.4.2.2. Competitive Scenario
      • 10.4.2.3. Regulatory Scenario
      • 10.4.2.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.4.3. Canada
      • 10.4.3.1. Key Country Dynamics
      • 10.4.3.2. Competitive Scenario
      • 10.4.3.3. Regulatory Scenario
      • 10.4.3.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.4.4. Mexico
      • 10.4.4.1. Key Country Dynamics
      • 10.4.4.2. Competitive Scenario
      • 10.4.4.3. Regulatory Scenario
      • 10.4.4.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 10.5. Europe
    • 10.5.1. Europe Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.5.2. UK
      • 10.5.2.1. Key Country Dynamics
      • 10.5.2.2. Competitive Scenario
      • 10.5.2.3. Regulatory Scenario
      • 10.5.2.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.5.3. Germany
      • 10.5.3.1. Key Country Dynamics
      • 10.5.3.2. Competitive Scenario
      • 10.5.3.3. Regulatory Scenario
      • 10.5.3.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.5.4. France
      • 10.5.4.1. Key Country Dynamics
      • 10.5.4.2. Competitive Scenario
      • 10.5.4.3. Regulatory Scenario
      • 10.5.4.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.5.5. Italy
      • 10.5.5.1. Key Country Dynamics
      • 10.5.5.2. Competitive Scenario
      • 10.5.5.3. Regulatory Scenario
      • 10.5.5.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.5.6. Spain
      • 10.5.6.1. Key Country Dynamics
      • 10.5.6.2. Competitive Scenario
      • 10.5.6.3. Regulatory Scenario
      • 10.5.6.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.5.7. Denmark
      • 10.5.7.1. Key Country Dynamics
      • 10.5.7.2. Competitive Scenario
      • 10.5.7.3. Regulatory Scenario
      • 10.5.7.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.5.8. Sweden
      • 10.5.8.1. Key Country Dynamics
      • 10.5.8.2. Competitive Scenario
      • 10.5.8.3. Regulatory Scenario
      • 10.5.8.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.5.9. Norway
      • 10.5.9.1. Key Country Dynamics
      • 10.5.9.2. Competitive Scenario
      • 10.5.9.3. Regulatory Scenario
      • 10.5.9.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 10.6. Asia Pacific
    • 10.6.1. Asia Pacific Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.6.2. China
      • 10.6.2.1. Key Country Dynamics
      • 10.6.2.2. Competitive Scenario
      • 10.6.2.3. Regulatory Scenario
      • 10.6.2.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.6.3. Japan
      • 10.6.3.1. Key Country Dynamics
      • 10.6.3.2. Competitive Scenario
      • 10.6.3.3. Regulatory Scenario
      • 10.6.3.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.6.4. India
      • 10.6.4.1. Key Country Dynamics
      • 10.6.4.2. Competitive Scenario
      • 10.6.4.3. Regulatory Scenario
      • 10.6.4.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.6.5. Australia
      • 10.6.5.1. Key Country Dynamics
      • 10.6.5.2. Competitive Scenario
      • 10.6.5.3. Regulatory Scenario
      • 10.6.5.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.6.6. South Korea
      • 10.6.6.1. Key Country Dynamics
      • 10.6.6.2. Competitive Scenario
      • 10.6.6.3. Regulatory Scenario
      • 10.6.6.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.6.7. Thailand
      • 10.6.7.1. Key Country Dynamics
      • 10.6.7.2. Competitive Scenario
      • 10.6.7.3. Regulatory Scenario
      • 10.6.7.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 10.7. Latin America
    • 10.7.1. Latin America Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.7.2. Brazil
      • 10.7.2.1. Key Country Dynamics
      • 10.7.2.2. Competitive Scenario
      • 10.7.2.3. Regulatory Scenario
      • 10.7.2.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.7.3. Argentina
      • 10.7.3.1. Key Country Dynamics
      • 10.7.3.2. Competitive Scenario
      • 10.7.3.3. Regulatory Scenario
      • 10.7.3.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 10.8. MEA
    • 10.8.1. MEA Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.8.2. South Africa
      • 10.8.2.1. Key Country Dynamics
      • 10.8.2.2. Competitive Scenario
      • 10.8.2.3. Regulatory Scenario
      • 10.8.2.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.8.3. Saudi Arabia
      • 10.8.3.1. Key Country Dynamics
      • 10.8.3.2. Competitive Scenario
      • 10.8.3.3. Regulatory Scenario
      • 10.8.3.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.8.4. UAE
      • 10.8.4.1. Key Country Dynamics
      • 10.8.4.2. Competitive Scenario
      • 10.8.4.3. Regulatory Scenario
      • 10.8.4.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 10.8.5. Kuwait
      • 10.8.5.1. Key Country Dynamics
      • 10.8.5.2. Competitive Scenario
      • 10.8.5.3. Regulatory Scenario
      • 10.8.5.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)

Chapter 11. Competitive Landscape

  • 11.1. Market Participant Categorization
    • 11.1.1. Market Leaders
    • 11.1.2. Emerging Players
  • 11.2. Service Heat Map Analysis (a comparative analysis of the players together)
  • 11.3. Company Profiles
    • 11.3.1. Boehringer Ingelheim GmbH
      • 11.3.1.1. Company Overview
      • 11.3.1.2. Financial Performance
      • 11.3.1.3. Service Benchmarking
      • 11.3.1.4. Strategic Initiatives
    • 11.3.2. Boehringer Ingelheim GmbH
      • 11.3.2.1. Company Overview
      • 11.3.2.2. Financial Performance
      • 11.3.2.3. Service Benchmarking
      • 11.3.2.4. Strategic Initiatives
    • 11.3.3. Vetter Pharma
      • 11.3.3.1. Company Overview
      • 11.3.3.2. Financial Performance
      • 11.3.3.3. Service Benchmarking
      • 11.3.3.4. Strategic Initiatives
    • 11.3.4. Recipharm AB
      • 11.3.4.1. Company Overview
      • 11.3.4.2. Financial Performance
      • 11.3.4.3. Service Benchmarking
      • 11.3.4.4. Strategic Initiatives
    • 11.3.5. Aenova Group
      • 11.3.5.1. Company Overview
      • 11.3.5.2. Financial Performance
      • 11.3.5.3. Service Benchmarking
      • 11.3.5.4. Strategic Initiatives
    • 11.3.6. Fresenius Kabi
      • 11.3.6.1. Company Overview
      • 11.3.6.2. Financial Performance
      • 11.3.6.3. Service Benchmarking
      • 11.3.6.4. Strategic Initiatives
    • 11.3.7. Famar
      • 11.3.7.1. Company Overview
      • 11.3.7.2. Financial Performance
      • 11.3.7.3. Service Benchmarking
      • 11.3.7.4. Strategic Initiatives
    • 11.3.8. NextPharma Technologies
      • 11.3.8.1. Company Overview
      • 11.3.8.2. Financial Performance
      • 11.3.8.3. Service Benchmarking
      • 11.3.8.4. Strategic Initiatives
    • 11.3.9. Ajinomoto Bio-Pharma Services
      • 11.3.9.1. Company Overview
      • 11.3.9.2. Financial Performance
      • 11.3.9.3. Service Benchmarking
      • 11.3.9.4. Strategic Initiatives
    • 11.3.10. PCI Pharma Services
      • 11.3.10.1. Company Overview
      • 11.3.10.2. Financial Performance
      • 11.3.10.3. Service Benchmarking
      • 11.3.10.4. Strategic Initiatives
    • 11.3.11. IDT Biologika
      • 11.3.11.1. Company Overview
      • 11.3.11.2. Financial Performance
      • 11.3.11.3. Service Benchmarking
      • 11.3.11.4. Strategic Initiatives
    • 11.3.12. Alcami Corporation
      • 11.3.12.1. Company Overview
      • 11.3.12.2. Financial Performance
      • 11.3.12.3. Service Benchmarking
      • 11.3.12.4. Strategic Initiatives
    • 11.3.13. Fareva Group
      • 11.3.13.1. Company Overview
      • 11.3.13.2. Financial Performance
      • 11.3.13.3. Service Benchmarking
      • 11.3.13.4. Strategic Initiatives
    • 11.3.14. Eurofins CDMO
      • 11.3.14.1. Company Overview
      • 11.3.14.2. Financial Performance
      • 11.3.14.3. Service Benchmarking
      • 11.3.14.4. Strategic Initiatives
    • 11.3.15. Siegfried Holding AG
      • 11.3.15.1. Company Overview
      • 11.3.15.2. Financial Performance
      • 11.3.15.3. Service Benchmarking
      • 11.3.15.4. Strategic Initiatives

List of Figures

  • Fig. 1 Information Procurement
  • Fig. 2 Primary Research Pattern
  • Fig. 3 Market Research Approaches
  • Fig. 4 Value Chain-Based Sizing & Forecasting
  • Fig. 5 Market Formulation & Validation
  • Fig. 6 Sterile Injectables CDMO, Market Segmentation
  • Fig. 7 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 8 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 9 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • Fig. 10 Porter's Five Forces Analysis
  • Fig. 11 Regional Marketplace: Key Takeaways
  • Fig. 12 Global Sterile Injectables CDMO, for Small Molecule, 2018 - 2030 (USD Million)
  • Fig. 13 Global Sterile Injectables CDMO, for Large Molecule, 2018 - 2030 (USD Million)
  • Fig. 14 Global Sterile Injectables CDMO, for Sterile Liquid Injectables, 2018 - 2030 (USD Million)
  • Fig. 15 Global Sterile Injectables CDMO, for Pre-filled Syringes, 2018 - 2030 (USD Million)
  • Fig. 16 Global Sterile Injectables CDMO, for Vials and Ampoules, 2018 - 2030 (USD Million)
  • Fig. 17 Global Sterile Injectables CDMO, for Contract Development, 2018 - 2030 (USD Million)
  • Fig. 18 Global Sterile Injectables CDMO, for Contract Manufacturing, 2018 - 2030 (USD Million)
  • Fig. 19 Global Sterile Injectables CDMO, for Packaging, 2018 - 2030 (USD Million)
  • Fig. 20 Global Sterile Injectables CDMO, for Quality Control and Assurance, 2018 - 2030 (USD Million)
  • Fig. 21 Global Sterile Injectables CDMO, for Lyophilization Services, 2018 - 2030 (USD Million)
  • Fig. 22 Global Sterile Injectables CDMO, for Oncology, 2018 - 2030 (USD Million)
  • Fig. 23 Global Sterile Injectables CDMO, for Central Nervous System Diseases, 2018 - 2030 (USD Million)
  • Fig. 24 Global Sterile Injectables CDMO, for Infectious Disorders, 2018 - 2030 (USD Million)
  • Fig. 25 Global Sterile Injectables CDMO, for Musculoskeletal Diseases, 2018 - 2030 (USD Million)
  • Fig. 26 Global Sterile Injectables CDMO, for Others, 2018 - 2030 (USD Million)
  • Fig. 27 Global Sterile Injectables CDMO, for Subcutaneous (SC), 2018 - 2030 (USD Million)
  • Fig. 28 Global Sterile Injectables CDMO, for Intravenous (IV), 2018 - 2030 (USD Million)
  • Fig. 29 Global Sterile Injectables CDMO, for Intramuscular (IM), 2018 - 2030 (USD Million)
  • Fig. 30 Global Sterile Injectables CDMO, for Others, 2018 - 2030 (USD Million)
  • Fig. 31 Global Sterile Injectables CDMO, for Pharmaceutical Companies, 2018 - 2030 (USD Million)
  • Fig. 32 Global Sterile Injectables CDMO, for Biopharmaceutical Companies, 2018 - 2030 (USD Million)
  • Fig. 33 Global Sterile Injectables CDMO, for Others, 2018 - 2030 (USD Million)
  • Fig. 34 Regional Outlook, 2023 & 2030
  • Fig. 35 North America Sterile Injectables CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 U.S. Sterile Injectables CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Canada Sterile Injectables CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Mexico Sterile Injectables CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Europe Sterile Injectables CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Germany Sterile Injectables CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 UK Sterile Injectables CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 France Sterile Injectables CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Italy Sterile Injectables CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Spain Sterile Injectables CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Denmark Sterile Injectables CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Sweden Sterile Injectables CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Norway Sterile Injectables CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Asia Pacific Sterile Injectables CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Japan Sterile Injectables CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 China Sterile Injectables CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 India Sterile Injectables CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Australia Sterile Injectables CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 South Korea Sterile Injectables CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Thailand Sterile Injectables CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Latin America Sterile Injectables CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Brazil Sterile Injectables CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Argentina Sterile Injectables CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Middle East and Africa Sterile Injectables CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 South Africa Sterile Injectables CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 Saudi Arabia Sterile Injectables CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 UAE Sterile Injectables CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 62 Kuwait Sterile Injectables CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)